IMRX
What one share of Immuneering holds
Pharmaceutical Preparations
We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies.
Immuneering’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.98 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.97 |
| Cash and investments | $0.64 |
| Book value | $2.95 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.47 | −$3.44 | $0.01 | −$2.96 | — | −$4.54 |
| 2021 | $0.15 | −$2.46 | $0.00 | −$2.27 | — | $11.46 |
| 2022 | $0.01 | −$1.91 | $0.03 | −$1.70 | — | $4.16 |
| 2023 | $0.00 | −$1.88 | $0.01 | −$1.74 | — | $3.19 |
| 2024 | — | −$2.04 | $0.00 | −$1.84 | — | $1.38 |
| 2025 | — | −$1.27 | $0.00 | −$1.03 | — | $4.96 |